COPD, Food and Drug Administration
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary disease received approval from the Food and Drug Administration.
New schizophrenia drug gets FDA approval, taking novel approach to treating brain disorder
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of drugs for schizophrenia in more than 30 years.
FDA Approves Dupixent for Some Patients Struggling With COPD Symptoms
Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies said on Friday.
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive Pulmonary Disease Treatment
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved
Sanofi blockbuster drug wins clearance in US for lung disease
Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after a similar decision by European regulators.
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
Sanofi recorded 10.72 billion euros ($11.94 billion) in sales for Dupixent in 2023, which includes Regeneron's share. Analysts on average expect Dupixent, by far Sanofi's best-selling drug, to generate more than 21 billion euros in sales in 2030,
FDA issues recall notices for two brands of pet food
FDA Lifts Clinical Hold On BMF-219
US FDA approves GE HealthCare's diagnostic drug for heart disease
The U.S. Food and Drug Administration approved GE HealthCare's diagnostic drug for use in detection of coronary artery ...
In a Victory for the Free Market, FDA Approves New Schizophrenia Drug
Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...
Courthouse News Service37m
Ninth Circuit sides with FDA in oversight of ‘liquid magic’ stem cell therapy
The panel agreed with the FDA that the treatment in which a patient's tissue is processed doesn't fall under the same ...
STAT2h
The FDA is ‘making sandwiches,’ ‘breakfast salad’ in DC, and what keeps us from choking on food
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. In a new ...
KALW3m
A new kind of drug for schizophrenia promises fewer side effects
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
FDA Approves New Schizophrenia Drug in 70-Year First
The treatment offers hope to thousands of patients who do not respond to existing medications, and has shown promise in treating other neurological disorders.
Dog food pulled from shelves nationwide: FDA
The U.S. Food and Drug Administration reports a pet food company is voluntarily withdrawing some of their beef and chicken ...
FDA Approves the First New Schizophrenia Drug in Decades
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
Check Your Fact on MSN3d
FACT CHECK: No, The Food And Drug Administration Did Not Say Mpox Is Fictional
A post shared on X claims the U.S. Food and Drug Administration (FDA) believes the mpox virus, or “monkeypox,” is fictional. Verdict: False The document cited in the article does not make this claim.